DF/HCC Program Affiliation

Co-Leader, Prostate Cancer Program

DF/HCC Associations

Member, Center Scientific Council

Research Abstract

In prostate cancer I am exploring the therapeutic gains possible from radiation dose escalation using conformal radiation therapy with the proton beam. Combinations of external radiation and brachytherapy are also under investigation. A large data-base of over 3000 patients has been developed and is being used to investigate prognostic factors in prostate cancer and to evaluate treatment outcomes. In bladder cancer, together with Dr W.U. Shipley, we have an active program exploring alternatives to cystectomy for muscle-invading tumors.

Publications

• Zietman AL, Tibbs MK, Dallow KC, Smith CT, Althausen AF, Zlotecki RA, Shipley WU. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol 1996 Aug; 40(2):159-62
  PMID: 8884970
• Frank SJ, Grimm PD, Sylvester JE, Merrick GS, Davis BJ, Zietman A, Moran BJ, Beyer DC, Roach M, Clarke DH, Stock RG, Robert Lee W, Michalski JM, Wallner KE, Hurwitz M, Potters L, Kuban DA, Prestidge BR, Vera R, Hathaway S, Blasko JC. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. Brachytherapy 2007 Jan-Mar; 6(1):2-8
  PMID: 17284379
• Ray ME, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Zelefsky MJ, Zietman AL, Kuban DA. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology 2006 Dec; 68(6):1257-62
  PMID: 17141830
• Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007 Feb 1; 67(2):327-33
  PMID: 17084558
• Horwitz EM, Levy LB, Thames HD, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer 2006 Oct 1; 107(7):1496-502
  PMID: 16944536
• Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky TM, Elshaikh M, Horwitz EM. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006 Aug 1; 65(5):1487-93
  PMID: 16750326
• Thames HD, Kuban DA, DeSilvio ML, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. Int J Radiat Oncol Biol Phys 2006 Jul 15; 65(4):975-81
  PMID: 16750319
• Shih HA, Harisinghani M, Zietman AL, Wolfgang JA, Saksena M, Weissleder R. Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys 2005 Nov 15; 63(4):1262-9
  PMID: 16253781
• Zietman AL, Chung CS, Coen JJ, Shipley WU. 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J Urol 2004 Jan; 171(1):210-4
  PMID: 14665878
• Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003 Nov 15; 57(4):915-28
  PMID: 14575822
• Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 2003 Nov 15; 57(4):929-43
  PMID: 14575823
• Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002 Feb; 87(2):599-603
  PMID: 11836291
• Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001 Sep 27; 345(13):948-55
  PMID: 11575286
• Chakravatri A, Zehr EM, Zietman AL, Shipley WU, Goggins WB, Finkelstein DM, Young RH, Chang EL, Wu CL. Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate cancer-results from a pilot study. Urology 2000 May; 55(5):635-8
  PMID: 10792068
• Shipley WU, Kaufman DS, Heney NM, Althausen AF, Zietman AL. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy. J Urol 1999 Aug; 162(2):445-50; discussion 450-1
  PMID: 10411054
• Zietman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 1997 Jul 15; 38(5):1067-70
  PMID: 9276373
• Zietman AL, Nakfoor BM, Prince EA, Gerweck LE. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J Sci Am 1997 Jan-Feb; 3(1):31-6
  PMID: 9072305
• Edelstein RA, Zietman AL, de las Morenas A, Krane RJ, Babayan RK, Dallow KC, Traish A, Moreland RB. Implications of prostate micrometastases in pelvic lymph nodes: an archival tissue study. Urology 1996 Mar; 47(3):370-5
  PMID: 8633404
• Zietman AL, Coen JJ, Ferry JA, Scully RE, Kaufman DS, McGovern FG. The management and outcome of stage IAE nonHodgkin's lymphoma of the testis. J Urol 1996 Mar; 155(3):943-6
  PMID: 8583613
• Zietman AL, Dallow KC, McManus PA, Heney NM, Shipley WU. Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Urology 1996 Feb; 47(2):236-9
  PMID: 8607241
• Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, Young RH, Shipley JW, Zietman AL, Biggs PJ. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995 Apr 30; 32(1):3-12
  PMID: 7721636
• Zietman AL, Shipley WU, Coen JJ. Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup. J Urol 1994 Nov; 152(5 Pt 2):1806-12
  PMID: 7523726
• Shipley WU, Zietman AL, Hanks GE, Coen JJ, Caplan RJ, Won M, Zagars GK, Asbell SO. Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor. J Urol 1994 Nov; 152(5 Pt 2):1799-805
  PMID: 7933239
• Centeno BA, Zietman AL, Shipley WU, Sobczak ML, Shipley JW, Preffer FI, Boyle BJ, Colvin RB. Flow cytometric analysis of DNA ploidy, percent S-phase fraction, and total proliferative fraction as prognostic indicators of local control and survival following radiation therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 1994 Sep 30; 30(2):309-15
  PMID: 7928459
• Willett CG, Zietman AL, Shipley WU, Coen JJ. The effect of pelvic radiation therapy on serum levels of prostate specific antigen. J Urol 1994 Jun; 151(6):1579-81
  PMID: 7514692
• Zietman AL, Edelstein RA, Coen JJ, Babayan RK, Krane RJ. Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 1994 Jun; 43(6):828-33
  PMID: 7515206
• Zietman AL, Coen JJ, Shipley WU, Willett CG, Efird JT. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994 Mar; 151(3):640-5
  PMID: 7508522
• Taghian A, Budach W, Zietman A, Freeman J, Gioioso D, Ruka W, Suit HD. Quantitative comparison between the transplantability of human and murine tumors into the subcutaneous tissue of NCr/Sed-nu/nu nude and severe combined immunodeficient mice. Cancer Res 1993 Oct 15; 53(20):5012-7
  PMID: 8402692
• Zietman AL, Coen JJ, Shipley WU, Althausen AF. Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: analysis of freedom from PSA failure. Urology 1993 Sep; 42(3):292-8; discussion 298-9
  PMID: 7691014
• Zietman AL, Shipley WU, Willett CG. Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications. Cancer 1993 Feb 1; 71(3 Suppl):959-69
  PMID: 7679046
• Zietman AL, Linggood RM, Brookes AR, Convery K, Piro A. Radiation therapy in the management of early stage Hodgkin's disease presenting in later life. Cancer 1991 Nov 1; 68(9):1869-73
  PMID: 1913538
• Zietman AL, Suit HD, Okunieff PG, Donnelly SM, Dieman S, Webster S. The life shortening effects of treatment with doxorubicin and/or local irradiation on a cohort of young C3Hf/Sed mice. Eur J Cancer 1991; 27(6):778-81
  PMID: 1829923
• Okunieff P, Zietman A, Kahn J, Singer S, Neuringer LJ, Levine RA, Evans FE. Lack of efficacy of water-suppressed proton nuclear magnetic resonance spectroscopy of plasma for the detection of malignant tumors. N Engl J Med 1990 Apr 5; 322(14):953-8
  PMID: 2314447
• Zietman AL, Suit HD, Tomkinson KN, Thames HD, Sedlacek RS. The response of two human tumor xenografts to fractionated irradiation. The derivation of alpha/beta ratios from growth delay, tumor control, and in vitro cell survival assays. Int J Radiat Oncol Biol Phys 1990 Mar; 18(3):569-75
  PMID: 2318689
• Silobrcic V, Zietman AL, Ramsay JR, Suit HD, Sedlacek RS. Residual immunity of athymic NCr/Sed nude mice and the xenotransplantation of human tumors. Int J Cancer 1990 Feb 15; 45(2):325-33
  PMID: 2406204
• Suit HD, Zietman A, Tomkinson K, Ramsay J, Gerweck L, Sedlacek R. Radiation response of xenografts of a human squamous cell carcinoma and a glioblastoma multiforme: a progress report. Int J Radiat Oncol Biol Phys 1990 Feb; 18(2):365-73
  PMID: 2154419
• Ramsay J, Zietman A, Preffer F, Suit HD. The growth and cell kinetics of a secondary tumor after radiation or surgical treatment of the primary tumor. Int J Radiat Oncol Biol Phys 1989 Oct; 17(4):809-13
  PMID: 2777671
• Lauk S, Zietman A, Skates S, Fabian R, Suit HD. Comparative morphometric study of tumor vasculature in human squamous cell carcinomas and their xenotransplants in athymic nude mice. Cancer Res 1989 Aug 15; 49(16):4557-61
  PMID: 2743340
• Suit HD, Sedlacek RS, Zietman A. Quantitative transplantation assays of spontaneous tumors of the C3H mouse as allografts in athymic NCr/Sed-nu/nu nude mice and isografts in C3Hf/Sed mice. Cancer Res 1988 Aug 15; 48(16):4525-8
  PMID: 3293775